Resveratrol Inhibits Human Visceral Preadipocyte Proliferation and Differentiation in vitro

Abstract Visceral obesity is a high‐risk factor for diabetes and metabolic syndrome. Resveratrol, a natural polyphenolic compound, has been reported to inhibit preadipocyte differentiation. However, the effect of resveratrol on human visceral preadipocyte (HPA‐v) differentiation remains largely unknown. LIM domain only 3 ( LMO3 ) promotes human preadipocyte differentiation by enhancing peroxisome proliferator‐activated receptor γ (PPARγ) transcriptional activity, which is the master regulator of adipogenesis. The purpose of our study was to determine the effect of resveratrol (0–50 μM) on HPA‐v proliferation and differentiation, and the role of LMO3 in resveratrol‐mediated regulation of HPA‐v differentiation. Resveratrol inhibited HPA‐v proliferation and differentiation in a dose‐dependent manner, and significantly decreased the mRNA expression levels of PPARG , CCAAT/enhancer‐binding protein α ( CEBPA ), fatty acid‐binding protein 4 ( FABP4 ), acetyl‐CoA carboxylase ( ACC ), and fatty acid synthase ( FAS ) ( p < 0.05) at 10, 20, and 50 μM. The mRNA and protein levels of LMO3 were significantly reduced by ≥20 μM resveratrol ( p < 0.05), and overexpression of LMO3 partially attenuated resveratrol‐induced reduction of HPA‐v differentiation by enhancing the PPARG transcriptional activity. Together, our study suggested that resveratrol reduced HPA‐v proliferation and differentiation, as well as LMO3, which was partially responsible for the reduction of resveratrol‐mediated adipocyte differentiation.